Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gupta, A.
Right arrow Articles by Phillips, P.C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gupta, A.
Right arrow Articles by Phillips, P.C.
Related Collections
Right arrow All Clinical trials
Right arrow All Oncology
Right arrow Nerve tumor
Right arrow Clinical trials Observational study (Cohort, Case control)
Right arrow Neurofibromatosis

Neurology 2003;60:130-132
© 2003 American Academy of Neurology
Brief Communications

Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1

A. Gupta, MD, B.H. Cohen, MD, P. Ruggieri, MD, R.J. Packer, MD and P.C. Phillips, MD

From the Department of Neurology (Drs. Gupta and Cohen), Brain Tumor Institute (Dr. Cohen), Radiology (Dr. Ruggieri), and Cancer Center (Dr. Cohen), Cleveland Clinic Foundation, OH; Department of Neurology (Dr. Packer), Children’s National Medical Center, Washington, DC; and Department of Neurology (Dr. Phillips), Children’s Hospital of Philadelphia, PA.

Address correspondence and reprint requests to Dr. Bruce H. Cohen, S-71, Department of Neurology, Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail: cohenb1{at}ccf.org

An open-label phase I trial of thalidomide (TL) in 20 patients with neurofibromatosis 1 (NF1) treated symptomatic plexiform neurofibroma (PNF). TL was well tolerated in doses up to 200 mg/d. Adverse reactions included transient somnolence in four, evanescent rash in two, and reversible mild peripheral neuropathy in two patients. Four patients showed less than 25% reduction in the tumor size. TL may have a role in the treatment of PNF and should be explored in a larger controlled study, possibly using higher doses of TL.




This article has been cited by other articles:


Home page
 NeurologyHome page
E. Dombi, J. Solomon, A. J. Gillespie, E. Fox, F. M. Balis, N. Patronas, B. R. Korf, D. Babovic-Vuksanovic, R. J. Packer, J. Belasco, et al.
NF1 plexiform neurofibroma growth rate by volumetric MRI: Relationship to age and body weight
Neurology, February 27, 2007; 68(9): 643 - 647.
[Abstract] [Full Text] [PDF]

Home page
 NeurologyHome page
D. Babovic-Vuksanovic, K. Ballman, V. Michels, P. McGrann, N. Lindor, B. King, J. Camp, V. Micic, N. Babovic, X. Carrero, et al.
Phase II trial of pirfenidone in adults with neurofibromatosis type 1
Neurology, November 28, 2006; 67(10): 1860 - 1862.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2003 by AAN Enterprises, Inc.